logo
  • Home
  • Technologies
    • Live Cell Encapsulation
    • Research & Development
    • Cancer
    • Diabetes
    • Cannabinoids
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
    • International Diabetes Consortium
  • Investor Relations
    • Overview
    • News / Events
    • Shareholder Calls/Updates
    • Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

News

    • 10 AUG 2020

    PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Cancer

    LAGUNA HILLS, CA, August 10, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has appointed José L. Iglesias M.D. as Consulting Chief

    Read more →
    • Posted in
    • News
    • 05 AUG 2020

    FDA Formally Accepts PharmaCyte Biotech’s Drug Master File for Company’s Pancreatic Cancer Therapy

    LAGUNA HILLS, CA, August 5, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Drug Master File (DMF) that its partner, Austrianova, filed with the U.S. Food and Drug Administration (FDA) has

    Read more →
    • Posted in
    • News
    • 29 JUL 2020

    PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests

    LAGUNA HILLS, CA July 29, 2020 (BUSINESS NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the COVID-19 Molecular tests it has licensed from Hai Kang Life Corporation Limited (Hai Kang) have received the CE

    Read more →
    • Posted in
    • News
    • 27 JUL 2020

    PharmaCyte Biotech Announces Submission of Drug Master File to FDA for Company’s Pancreatic Cancer Therapy

    LAGUNA HILLS, CA, July 27, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its partner, Austrianova, has submitted a Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA). The

    Read more →
    • Posted in
    • News
    • 13 JUL 2020

    PharmaCyte Biotech Successfully Completes Container Closure Integrity Test

    LAGUNA HILLS, Calif.–(BUSINESS WIRE)– PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the Container Closure Integrity (CCI) test that is required by the U.S. Food and Drug Administration (FDA) for its CypCaps™

    Read more →
    • Posted in
    • News
    • 08 JUL 2020

    PharmaCyte Biotech Successfully Completes Three-Month Stability Study

    LAGUNA HILLS, CA, July 8, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed the three-month product stability testing that is required by the U.S. Food and Drug Administration

    Read more →
    • Posted in
    • News
    • 23 JUN 2020

    PharmaCyte Biotech Provides IND Submission Update for Pancreatic Cancer Clinical Trial

    LAGUNA HILLS, CA, June 23, 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it is closing the gap in completing its Investigational New Drug application (IND) for its planned clinical trial in

    Read more →
    • Posted in
    • News
    • 15 JUN 2020

    PharmaCyte Biotech Successfully Accelerates Development of Container Closure Integrity Test for Pancreatic Cancer Clinical Trial Product

    LAGUNA HILLS, CA, June 15 , 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully accelerated the development of its Container Closure Integrity (CCI) test– an essential component of the

    Read more →
    • Posted in
    • News
    • 10 JUN 2020

    PharmaCyte Biotech Successfully Develops “Change History” for its Clinical Trial Product for Pancreatic Cancer

    LAGUNA HILLS, CA, June 10 , 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed development of the “change history” information and data for CypCaps™ (2nd generation product) compared

    Read more →
    • Posted in
    • News
    • 08 JUN 2020

    PharmaCyte Biotech Completes Final cGMP Audit of Manufacturing Facility for Pancreatic Cancer Clinical Trial Product

    LAGUNA HILLS, CA, June 8 , 2020 (BUSINESS WIRE) — PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that cGMP Validation, the company’s cGMP consultant, has completed its post manufacturing audit of the manufacturing facility in Thailand

    Read more →
    • Posted in
    • News
  • ‹
  • 1
  • 2
  • 3
  • 4
  • ›
  • »

Contact Us

PharmaCyte Biotech Inc.
23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92653
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS

Latest News

  • PharmaCyte Biotech Successfully Completes 1 Year Stability Study 2021-04-01T09:15:59-0400
  • PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product 2021-01-26T09:00:55-0400

Subscribe to Our Mailing List

* indicates required
Email Format